<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neck dissection for differentiated thyroid cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neck dissection for differentiated thyroid cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neck dissection for differentiated thyroid cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca S Sippel, MD, FACS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sally E Carty, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wenliang Chen, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 31, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H27139731"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Differentiated thyroid cancers, including papillary and follicular, account for &gt;90 percent of thyroid cancer patients [<a href="#rid1">1</a>]. While metastatic disease to regional nodes is frequently identified in patients with papillary thyroid cancer, it is very uncommon in patients with follicular cancer. </p><p>Cervical lymphadenectomy, or neck dissection, is the treatment of choice when there is evidence of lymph node metastasis from thyroid cancer. In certain situations, a neck dissection can also be performed "prophylactically" at the time of thyroidectomy to avoid a second operation due to recurrence. </p><p>In this topic, we discuss various neck dissection techniques and their applications. Techniques of thyroidectomy are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2157.html" rel="external">"Thyroidectomy"</a>.) </p><p class="headingAnchor" id="H1138017"><span class="h1">ANATOMY AND DEFINITIONS</span><span class="headingEndMark"> — </span>The neck is divided into six levels (I to VI) and six sublevels (A or B) with regard to its nodal contents  (<a class="graphic graphic_figure graphicRef58086" href="/z/d/graphic/58086.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef54099" href="/z/d/graphic/54099.html" rel="external">figure 2</a>) [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Level I – Submental (IA) and submandibular lymph nodes (IB).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Level II – Upper third of the jugular lymph nodes from the hyoid bone to the base of the skull. This includes those lymph nodes located anterior (IIA) and posterior (IIB) to the spinal accessory nerve.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Level III – Middle third of jugular lymph nodes, located between the cricoid cartilage and the hyoid bone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Level IV – Lower third of jugular lymph nodes, located from the clavicle to the cricoid cartilage.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Level V – Posterior triangle lymph nodes, located posterior to the sternocleidomastoid muscle, including spinal accessory nodes; above the cricoid cartilage (VA), supraclavicular, and transverse cervical nodes; and below the cricoid cartilage (VB).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Level VI – Central neck lymph nodes located between the carotid arteries from the innominate artery to the hyoid bone. This includes the pretracheal, prelaryngeal, and paratracheal lymph nodes.</p><p></p><p>A <strong>radical neck dissection</strong> involves the removal of all nodal and fibrofatty tissue from levels I to V, including sacrificing the sternocleidomastoid muscle, the spinal accessory nerve, and the internal jugular vein. </p><p>A <strong>modified radical neck dissection</strong> involves removal of all nodal and fibrofatty tissue from levels I to V but preserves one or more of the sternocleidomastoid muscle, the spinal accessory nerve, and the internal jugular vein. </p><p>For most patients with thyroid cancer, removal of the affected lymph nodes does not require sacrificing any of the critical structures. In addition, it is uncommon that a patient with thyroid cancer would require removal of level I lymph nodes. Therefore, most patients undergo a compartment-oriented <strong>selective neck dissection</strong>, which is removal of all of the fibroadipose tissue and lymphatic tissues en bloc from a given compartment (ie, central, lateral) within the neck, while preserving critical structures  (<a class="graphic graphic_figure graphicRef54099" href="/z/d/graphic/54099.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef87027" href="/z/d/graphic/87027.html" rel="external">figure 3</a>) [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A <strong>central neck dissection</strong> entails removal of the lymph nodes from level VI, including the prelaryngeal and pretracheal nodes, and at least one paratracheal lymph node basin. Central neck dissection may be unilateral or bilateral. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A <strong>lateral neck dissection</strong> includes the removal of the lymph nodes from level II through V.</p><p></p><p>Nonanatomical cervical lymph node resection, commonly referred to as "berry picking," where only the involved nodes are removed, should not be performed, because of a higher local recurrence rate compared with that of compartment-oriented neck dissections (100 versus 9 percent) [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H2908938354"><span class="h1">LYMPH NODE METASTASIS IN DIFFERENTIATED THYROID CANCER</span></p><p class="headingAnchor" id="H1293558287"><span class="h2">Incidence</span></p><p class="headingAnchor" id="H88586123"><span class="h3">Papillary thyroid cancer</span><span class="headingEndMark"> — </span>Metastatic disease to regional lymph nodes is common in patients with papillary thyroid cancer. Palpable nodal disease is present in approximately 5 to 10 percent of patients with papillary thyroid cancer; a preoperative neck ultrasound can detect lymph node disease in up to 30 percent of patients [<a href="#rid5">5-8</a>]. </p><p>Standard histologic techniques (hematoxylin and eosin stain) typically reveal positive lymph nodes in 20 to 50 percent of patients undergoing an elective neck dissection for papillary thyroid cancer [<a href="#rid9">9</a>]. However, after immunohistochemical evaluation (ie, cytokeratin stain), up to 90 percent of patients will have microscopic metastatic disease [<a href="#rid10">10-12</a>]. It appears that many patients have microscopic regional lymph node disease that never becomes clinically apparent. (See <a class="local">'Prognosis'</a> below and  <a class="medical medical_review" href="/z/d/html/7860.html" rel="external">"Papillary thyroid cancer: Clinical features and prognosis", section on 'Prognostic features'</a>.) </p><p class="headingAnchor" id="H455227359"><span class="h3">Follicular thyroid cancer</span><span class="headingEndMark"> — </span>By contrast, follicular thyroid cancer metastasizes via the hematogenous rather than the lymphatic route [<a href="#rid13">13</a>]. As a result, &lt;5 percent of patients with follicular thyroid cancer develop nodal metastasis. (See  <a class="medical medical_review" href="/z/d/html/7867.html" rel="external">"Follicular thyroid cancer (including oncocytic carcinoma of the thyroid)", section on 'Metastases'</a>.)</p><p class="headingAnchor" id="H1138097"><span class="h2">Pattern of spread</span><span class="headingEndMark"> — </span>Central neck, or level VI, lymph nodes are typically the first site of regional spread of papillary thyroid cancer [<a href="#rid11">11</a>]. Papillary thyroid cancer spreads in a stepwise fashion from the thyroid to the central neck and then laterally to the jugular chain nodes  (<a class="graphic graphic_figure graphicRef58086" href="/z/d/graphic/58086.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef54099" href="/z/d/graphic/54099.html" rel="external">figure 2</a>). Level III and level IV are the most common sites of nodal metastatic disease in the lateral neck compartment, while disease is rarely identified in level I nodes [<a href="#rid14">14</a>]. </p><p>If there is nodal involvement identified in the lateral neck, it is presumed that there is disease in the central neck as well. Thus, if nodal disease is identified in the lateral neck, both a central and lateral neck dissection should be performed.</p><p>"Skip" metastasis, in which lateral neck involvement is seen in the absence of central neck nodal disease, can occur in up to 22 percent of patients and is most commonly seen with superior pole thyroid tumors [<a href="#rid15">15,16</a>]. </p><p class="headingAnchor" id="H2323005578"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Cervical lymph node metastasis from papillary thyroid cancer is associated with several well-described factors, including multifocality, extrathyroidal extension, larger tumor size, younger age, aggressive variants, and the presence of <em>BRAF</em> mutation [<a href="#rid17">17-20</a>]. </p><p class="headingAnchor" id="H27139738"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>Metastatic disease to regional lymph nodes at the time of presentation may increase the risk of cervical recurrence but does not appear to negatively impact survival [<a href="#rid21">21-23</a>]. (See  <a class="medical medical_review" href="/z/d/html/7860.html" rel="external">"Papillary thyroid cancer: Clinical features and prognosis", section on 'Histology'</a> and  <a class="medical medical_review" href="/z/d/html/7867.html" rel="external">"Follicular thyroid cancer (including oncocytic carcinoma of the thyroid)", section on 'Lymph node involvement'</a>.) </p><p>Lymph node involvement in papillary thyroid cancer can be macroscopic (identified on preoperative imaging or intraoperative inspection) or microscopic (identified on pathologic review only). <strong>Macroscopic</strong> lymph node involvement is associated with a high rate of local recurrence (10 to 42 percent) [<a href="#rid21">21,22,24-27</a>]. Lymph node factors associated with a higher risk of local recurrence include more than five positive lymph nodes, high ratio of positive to negative lymph nodes (ie, lymph node ratio), and the presence of extranodal extension [<a href="#rid21">21,28</a>].</p><p>The association between <strong>microscopic</strong> nodal disease detected following a prophylactic neck dissection and recurrence of local lymph node disease is controversial [<a href="#rid24">24,25,29,30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In one trial, 181 patients without evidence of lymph node disease were randomly assigned to total thyroidectomy alone or total thyroidectomy plus a prophylactic central neck dissection [<a href="#rid31">31</a>]. Microscopic lymph node disease was identified in 46.2 percent of patients who underwent neck dissection. At five years, there was no difference in rates of structural recurrence or persistent disease between the two groups. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, in a multicenter retrospective study, 103 clinically node-negative patients who were treated with total thyroidectomy alone had a higher recurrence rate (3.9 percent) than 30 patients treated with total thyroidectomy plus a unilateral or bilateral central neck dissection (0 percent) [<a href="#rid32">32</a>]. Lymph nodes were positive in 23.3 percent of patients undergoing a unilateral dissection and 63.3 percent undergoing a bilateral dissection.</p><p></p><p>The prognosis of differentiated thyroid cancer remains excellent even in patients with lymph node involvement (&gt;90 percent 10 year survival) [<a href="#rid1">1,29</a>]. Metastatic disease to regional lymph nodes at the time of presentation does not appear to have a significant impact on overall survival [<a href="#rid21">21-23</a>]. As an example, the 5 and 10 year disease-specific survival rates in patients with lymph node metastasis from papillary thyroid cancer were similar to those in patients without lymph node metastasis (98 versus 100 percent and 95 versus 100 percent, respectively) [<a href="#rid29">29</a>]. </p><p>Metastatic disease to regional lymph nodes for patients &lt;45 years of age is not an independent risk factor for disease-specific survival [<a href="#rid23">23,29,33-38</a>]. In a retrospective review of 11,453 patients with papillary thyroid cancer, the four-year disease-specific survival for patients &lt;45 years old was 99 percent, independent of the presence or absence of lymph node involvement. Kaplan-Meier age-stratified subgroup analysis found age &gt;45 years to be associated with a higher mortality rate [<a href="#rid23">23</a>]. The four-year disease-specific survival was particularly worse for patients &gt;45 years old with positive nodes in the lateral and mediastinal compartments (level II to VA and VB/VII) compared with those with positive nodes in the central compartment (level VI). (See  <a class="medical medical_review" href="/z/d/html/7860.html" rel="external">"Papillary thyroid cancer: Clinical features and prognosis", section on 'Prognostic features'</a> and  <a class="medical medical_review" href="/z/d/html/7867.html" rel="external">"Follicular thyroid cancer (including oncocytic carcinoma of the thyroid)", section on 'Prognostic features'</a>.)</p><p class="headingAnchor" id="H28440921"><span class="h1">CHOOSING A NECK DISSECTION TECHNIQUE</span></p><p class="headingAnchor" id="H1148701169"><span class="h2">Staging evaluation</span><span class="headingEndMark"> — </span>A preoperative ultrasound to assess for regional nodal disease in the neck is an essential part of the staging workup of all patients with a preoperative diagnosis of thyroid cancer  (<a class="graphic graphic_diagnosticimage graphicRef73138" href="/z/d/graphic/73138.html" rel="external">image 1</a>) [<a href="#rid39">39,40</a>]. </p><p>Computed tomography (CT) scans and magnetic resonance imaging (MRI) scans are used selectively in the preoperative evaluation of patients with thyroid cancer and are most beneficial in patients with extensive nodal involvement or in patients with thick necks in whom the resolution of ultrasound may be limited [<a href="#rid41">41,42</a>]. </p><p>The staging of thyroid cancer and a review of the utility of ultrasonography are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7839.html" rel="external">"Differentiated thyroid cancer: Clinicopathologic staging"</a> and  <a class="medical medical_review" href="/z/d/html/7859.html" rel="external">"Overview of the clinical utility of ultrasonography in thyroid disease", section on 'Lymphadenopathy'</a>.)</p><p>At thyroidectomy, it is not uncommon to discover central compartment nodal disease not identified on preoperative ultrasound. Thus, the surgeon should always inspect the central compartment nodes and be prepared to perform central neck dissection if they appear abnormal. Suspected lymph node metastasis may be confirmed by intraoperative frozen section examination. </p><p>The decision to perform a neck dissection and the choice of a neck dissection technique are determined by whether and where lymph node metastasis has been detected  (<a class="graphic graphic_algorithm graphicRef113321" href="/z/d/graphic/113321.html" rel="external">algorithm 1</a>). </p><p class="headingAnchor" id="H15405236"><span class="h2">No known nodal disease</span></p><p class="headingAnchor" id="H1134212224"><span class="h3">Central neck compartment</span><span class="headingEndMark"> — </span>Patients with <strong>follicular</strong> thyroid cancer have a low risk of nodal disease (&lt;5 percent) [<a href="#rid13">13</a>]. Thus, in patients known to have follicular thyroid cancer preoperatively (which is an uncommon situation), a central neck dissection should <strong>not</strong> be performed prophylactically without any evidence of lymph node metastasis. Prophylactic central neck dissection is not appropriate for most patients receiving thyroidectomy for indeterminate fine-needle aspiration biopsy results. </p><p>A prophylactic central neck dissection (level VI) for patients with <strong>papillary</strong> thyroid cancer is controversial [<a href="#rid26">26,27,30-32,43-51</a>]. We use a selective approach, based upon patient risk factors and the experience level of the surgeon [<a href="#rid43">43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>We consider a prophylactic central neck dissection (ipsilateral or bilateral) in patients with large papillary thyroid cancer (T3 or T4 lesions)  (<a class="graphic graphic_table graphicRef110635" href="/z/d/graphic/110635.html" rel="external">table 1</a>) or the presence of extrathyroidal tumor extension. Some surgeons will perform a prophylactic neck dissection based on carrier status of <em>BRAF</em> mutations from a fine needle aspiration (FNA) sample, but this remains controversial. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We perform a near-total or total thyroidectomy <strong>without</strong> prophylactic central neck dissection in patients with small (T1 or T2) lesions and without high-risk features. </p><p></p><p>Our approach is consistent with the American Thyroid Association (ATA) consensus guidelines [<a href="#rid9">9</a>] and the American Association of Endocrine Surgeons guidelines [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment", section on 'Prophylactic lymph node dissection'</a> and  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management", section on 'Choice of surgical procedure'</a> and  <a class="medical medical_review" href="/z/d/html/7819.html" rel="external">"Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer"</a>.)</p><p>A prophylactic central neck dissection at the time of thyroid surgery may help avoid a reoperation but may increase perioperative morbidity, particularly when performed by less experienced surgeons [<a href="#rid53">53-55</a>]. While older studies suggested a reduced risk of nodal recurrence and improved survival with a prophylactic central neck dissection [<a href="#rid56">56,57</a>], such benefits were not demonstrated by other studies [<a href="#rid55">55</a>]. </p><p>A meta-analysis of 17 nonrandomized comparative studies showed that patients with papillary thyroid cancer without clinical evidence of nodal metastasis who underwent total thyroidectomy with prophylactic central neck dissection had a lower risk of locoregional recurrences (risk ratio [RR] 0.66, 95% CI 0.49-0.90), especially in the central neck compartment (RR 0.35, 95% CI 0.18-0.68), compared with those without neck dissection [<a href="#rid58">58</a>]. However, prophylactic central neck dissection was associated with higher rates of overall morbidity (odds ratio [OR] 2.56, 95% CI 1.75-3.74), including those of temporary (OR 2.37, 95% CI 1.89-2.96) and permanent hypocalcemia (OR 1.93, 95% CI 1.05-3.57). </p><p>In a randomized trial, 60 patients with clinically node-negative papillary thyroid cancer underwent total thyroidectomy with or without prophylactic central neck dissection [<a href="#rid59">59</a>]. Although 28 percent of patients who underwent neck dissection had microscopic lymph node involvement, the oncologic outcomes at one year were not different between the two groups. Another randomized trial failed to demonstrate any impact of prophylactic central neck dissection on nodal recurrence or persistence but did show that central neck dissection reduced the need for additional treatments with radioactive iodine [<a href="#rid31">31</a>]. (See <a class="local">'Morbidity rates'</a> below.)</p><p class="headingAnchor" id="H1009022605"><span class="h3">Lateral neck compartment</span><span class="headingEndMark"> — </span>Lateral neck lymph nodal involvement occurs in approximately 20 to 30 percent of patients with thyroid cancer<strong> </strong>[<a href="#rid60">60</a>]. Regional nodal disease is generally identified by ultrasound preoperatively or postoperatively. Because the lateral neck compartment is not entered during a total thyroidectomy, there is no added risk to doing a lateral neck dissection in a delayed fashion if disease is identified after the initial operation. </p><p>While microscopic disease is common in the lateral neck, routine lateral neck dissection has never been shown to benefit long-term survival [<a href="#rid21">21,43</a>].<strong> </strong>Given that lateral neck dissection is associated with considerable morbidity but no survival benefit, we reserve it for patients who have proven nodal disease in the lateral neck, rather than performing it prophylactically at the time of thyroid surgery. (See <a class="local">'Known nodal disease'</a> below.)</p><p class="headingAnchor" id="H233981886"><span class="h2">Known nodal disease</span><span class="headingEndMark"> — </span>A neck dissection for differentiated thyroid cancer (papillary and follicular) is performed as a therapeutic procedure when nodal disease is suspected based upon the clinical examination or ultrasound evaluation and confirmed with fine-needle aspiration (cytology and thyroglobulin washout). This is recommended by both the ATA and the National Comprehensive Cancer Network (NCCN) [<a href="#rid9">9,61</a>]. (See  <a class="medical medical_review" href="/z/d/html/7889.html" rel="external">"Thyroid biopsy", section on 'Lymphadenopathy'</a>.)</p><p>A therapeutic neck dissection can be performed with the initial thyroidectomy, as a (delayed) secondary procedure after the initial thyroidectomy, at the time of a local nodal recurrence in the absence of widespread or distant diseases, or as a reoperation in patients who have had a previous neck dissection in the same compartment [<a href="#rid62">62,63</a>]. (See  <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment", section on 'Therapeutic lymph node dissection'</a> and  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management", section on 'Choice of surgical procedure'</a>.)</p><p class="headingAnchor" id="H2471002449"><span class="h2">Recurrent nodal disease</span><span class="headingEndMark"> — </span>In patients who develop nodal or local recurrence after previous surgery for differentiated thyroid cancer, we perform surgical removal when feasible in order to avoid complications from continued tumor growth, to facilitate surveillance of thyroglobulin levels, and to minimize the amount of radioactive iodine that patients receive. </p><p>However, due to the risks of reoperation, we usually do not consider operative intervention until the lesion is &gt;8 to 10 mm in size. For lesions &lt;1.5 cm, we utilize the blue dye technique or same-day ultrasonographic skin marking to facilitate intraoperative localization. (See <a class="local">'Preoperative localization of recurrent disease'</a> below.)</p><p>The following approach is consistent with the current ATA guidelines [<a href="#rid9">9</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>In the clinical setting of a biopsy-proven recurrence ≥8 mm in the central neck and ≥10 mm in the lateral neck, we advocate surgical resection of the lesion. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with nodal recurrence in a field that has not been dissected, we perform a formal compartment-oriented neck dissection. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with biopsy-proven nodal recurrence following thyroidectomy and a formal neck dissection, we proceed with a focused removal of the involved lymph node(s) and any adjacent nodes. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the clinical setting of a biopsy-proven recurrence &lt;8 mm in the central neck and &lt;10 mm in the lateral neck, we perform a formal compartment neck dissection if the patient has not had a prior lymphadenectomy. If the recurrence is in a reoperative bed, we favor observation and serial imaging until the lesion enlarges further. We then perform a focused removal of the involved lymph node(s) or a therapeutic lymph node dissection of that level if the level has not been previously dissected.</p><p></p><p>Patients with a low risk of recurrence may be managed nonoperatively with serial imaging. In 166 patients with suspected nodal recurrences who were followed without surgery, only 29 percent of the lesions grew by &gt;3 mm in 3.5 years, and 14 percent resolved [<a href="#rid64">64</a>]. Another option that can be used in case of isolated recurrence, especially if the patient is a high-risk operative candidate, is ethanol ablation [<a href="#rid65">65-67</a>]. </p><p class="headingAnchor" id="H1138723"><span class="h1">PREOPERATIVE PREPARATION</span></p><p class="headingAnchor" id="H1138731"><span class="h2">Prophylactic antibiotics</span><span class="headingEndMark"> — </span>Thyroidectomy and neck dissection are both classified as clean operations, with the risk of infection &lt;1 percent [<a href="#rid68">68</a>]. Because of the low infection risk, routine prophylactic antibiotics have not been proven beneficial. Nevertheless, preoperative antibiotics can be administered to select patients who are at high risk of developing wound infections, including those who have medical comorbidities or are immunocompromised. (See  <a class="medical medical_review" href="/z/d/html/2157.html" rel="external">"Thyroidectomy", section on 'Antibiotics'</a>.)</p><p class="headingAnchor" id="H1138747"><span class="h2">Venous thrombosis prophylaxis</span><span class="headingEndMark"> — </span>Patients undergoing a regional thyroid lymphadenectomy are at a very low risk for developing a deep venous thrombosis (DVT). The reported risk of DVT in this population is 0.16 percent [<a href="#rid69">69</a>], while the risk of bleeding complications is higher (0.96 percent). Thus, the risks and benefits of DVT prophylaxis must be balanced carefully in this population. </p><p>For high-risk patients, we use a preoperative subcutaneous dose of <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> in addition to intermittent pneumatic compression devices. Prevention of DVT is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.) </p><p class="headingAnchor" id="H2892454"><span class="h2">Preoperative localization of recurrent disease</span><span class="headingEndMark"> — </span>Distortion of the tissue planes due to scarring makes a reoperation for metachronous recurrence of nodal disease technically challenging. Preoperative localization of recurrent disease is a useful adjunct for any reoperative neck dissection [<a href="#rid70">70-74</a>]. </p><p>Ultrasound guidance can be used preoperatively to inject either a very small amount of blue dye [<a href="#rid75">75</a>] or a charcoal suspension [<a href="#rid76">76</a>] to mark the location of the pathologic nodes, which allows the surgeon to localize the pathologic nodes among the scar tissues within the neck. Intraoperative ultrasound can also be used to augment localization. (See  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management", section on 'Management of persistent or recurrent disease'</a>.)</p><p>A prospective study of 10 patients with isolated, nonpalpable recurrences found that injection of blue dye under ultrasound guidance was feasible and detected nodes as small as 6 mm without complications [<a href="#rid75">75</a>]. Another prospective study of 15 consecutive patients found that colloidal charcoal injected under ultrasound guidance 1 to 15 days before the operation could be identified in or near 16 of 19 (84 percent) recurrent lesions [<a href="#rid76">76</a>]. </p><p class="headingAnchor" id="H27139831"><span class="h1">CENTRAL COMPARTMENT NECK DISSECTION</span></p><p class="headingAnchor" id="H1140098"><span class="h2">Extent of central neck dissection</span><span class="headingEndMark"> — </span>The central compartment neck dissection extends superiorly to the hyoid bone and inferiorly to the innominate (brachiocephalic) artery  (<a class="graphic graphic_figure graphicRef58086" href="/z/d/graphic/58086.html" rel="external">figure 1</a>). The lateral border of dissection is the ipsilateral carotid artery, the anterior border is the superficial layer of the deep cervical fascia, and the posterior border is the deep layer of the deep cervical fascia, which may be deep to the carotid artery. The number of lymph nodes contained within the central neck varies greatly between patients. An autopsy study identified between 1 and 16 lymph nodes in the central neck, with 0 to 7 lymph nodes in each paratracheal space and an additional 0 to 8 in the pretracheal space [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H27139898"><span class="h2">Technique for central neck dissection</span><span class="headingEndMark"> — </span>An initial central neck dissection is typically performed with the same patient positioning, type of incision, exposure, drains, and closure as described for thyroidectomy. The approach to thyroidectomy is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2157.html" rel="external">"Thyroidectomy", section on 'Dissection of the thyroid gland'</a>.)</p><p>Although the anatomic landmarks are the same for initial and reoperative procedures, the landmarks may be distorted and challenging to identify if the neck dissection is performed in the same compartment after a previous cervical operation such as thyroidectomy, parathyroidectomy, carotid endarterectomy, cervical disc surgery, or lymphadenectomy. Thus, in the reoperative setting, a fresh incision can be made directly over a localized level VI lymph node in order to avoid extensive dissection and complications [<a href="#rid70">70</a>]. Furthermore, such reoperations should be performed by a surgeon skilled in reoperative thyroid operations. </p><p>The standard approach to initial neck dissection for patients with thyroid cancer is compartment oriented. The general principles of a central compartment neck dissection include  (<a class="graphic graphic_figure graphicRef86364" href="/z/d/graphic/86364.html" rel="external">figure 4</a>) [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Identifying the recurrent laryngeal nerve at the posterior suspensory ligament of Berry (lateral thyrohyoid ligament)  (<a class="graphic graphic_figure graphicRef74541" href="/z/d/graphic/74541.html" rel="external">figure 5</a>). The recurrent laryngeal nerve lies lateral to the ligament. Preserve the recurrent laryngeal nerve caudally along its entire course.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dissecting the fibroadipose tissues anterior and medial to the recurrent laryngeal nerve and its branches, medially to laterally, using an en bloc technique and gentle traction on the specimen. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dissecting the tissues posterior to the recurrent laryngeal nerve laterally and inferiorly, sweeping the mass of lymphatic and fibroareolar tissues medially and inferiorly from the level of the hyoid bone superiorly to the innominate artery inferiorly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identifying the upper (embryologically superior) parathyroid gland, typically 1 to 2 cm cranial to the junction of the recurrent laryngeal nerve with the inferior thyroid artery, and within 1 cm of the entry point for the recurrent laryngeal nerve into the ligament of Berry and the cricoid cartilage  (<a class="graphic graphic_figure graphicRef56752" href="/z/d/graphic/56752.html" rel="external">figure 6</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identifying the superior thyroid artery, which provides arterial blood supply to the upper parathyroid glands in most patients. Preserve the adjacent superior laryngeal nerve and its branches as well as the parathyroid gland and its vascular pedicle [<a href="#rid78">78</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identifying the inferior parathyroid gland, located anterior to the recurrent laryngeal nerve. The inferior gland is most often found in the thyrothymic tract or just inside the thyroid capsule on the inferior portion of the thyroid lobes. Free the gland from its medial fibroareolar attachments, and sweep it laterally on its vascular pedicle. The blood supply is generally from the inferior thyroid artery, which is nearly always preserved. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preserving the inferior parathyroid gland. Every attempt should be made to preserve the parathyroid gland in situ, if feasible. Often, the lower parathyroid gland can be mobilized laterally and preserved with its inferior pedicle. However, when there is bulky central neck nodal disease, this can be challenging. If a parathyroid gland becomes dusky in color, indicating devascularization, an autotransplantation can be performed after confirming that it is indeed a parathyroid gland by intraoperative frozen section. Most surgeons agree it is difficult to preserve the lower parathyroid glands in situ, and some advocate routine autotransplantation [<a href="#rid79">79</a>]. (See  <a class="medical medical_review" href="/z/d/html/2157.html" rel="external">"Thyroidectomy", section on 'Parathyroid autotransplantation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dissecting caudally toward the sternal notch. If available, the Harmonic scalpel cutting and coagulation device may facilitate the separation of central compartment contents from the lateral strap muscle fibers as well as help in the management of associated small blood vessels. Identify and preserve the recurrent laryngeal nerve along its course from the ligament of Berry to the thoracic outlet while resecting all lymphatic tissues anterior to it.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Including the thymic tissue with the specimen, especially if abnormal nodes are palpated within the gland. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Do <strong>not</strong> "berry pick." Isolated removal of only the visible or clinical involved lymph nodes violates the principles of compartment-oriented dissection and will result in higher recurrence rates [<a href="#rid4">4</a>]. </p><p></p><p class="headingAnchor" id="H27139926"><span class="h1">THERAPEUTIC LATERAL COMPARTMENT NECK DISSECTION</span><span class="headingEndMark"> — </span>A compartment-oriented approach is standard when performing a lateral neck dissection; there is no role for "berry picking" of lymph nodes  (<a class="graphic graphic_figure graphicRef54099" href="/z/d/graphic/54099.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef86365" href="/z/d/graphic/86365.html" rel="external">figure 7</a>). In most cases, a lateral compartment neck dissection for thyroid cancer does not entail a radical or modified radical neck dissection. (See <a class="local">'Anatomy and definitions'</a> above.) </p><p class="headingAnchor" id="H16738719"><span class="h2">Extent of lateral compartmental dissection</span><span class="headingEndMark"> — </span>The extent of a lateral compartment lymph node dissection for <strong>papillary</strong> thyroid cancer is controversial [<a href="#rid80">80</a>]. The extent of dissection generally depends upon the location of the nodal disease (eg, most commonly level III and IV) (see <a class="local">'Pattern of spread'</a> above). No randomized trials have been performed to determine the appropriate extent of the lateral compartmental dissection.</p><p>The consensus statement from the American Thyroid Association recommends that a comprehensive lateral neck dissection for thyroid cancer include removal of lymph nodes from levels IIA, III, IV, and VB [<a href="#rid81">81</a>]. The highest rates of nodal involvement include levels III (77 percent), IV (62 percent), IIA (49 percent), and VB (40 percent) [<a href="#rid82">82,83</a>]. </p><p>While some authors support a comprehensive nodal dissection of levels II to V for all patients with thyroid cancer [<a href="#rid81">81,83</a>], we advocate a more selective approach with a compartment-oriented dissection determined by the extent of nodal involvement identified on preoperative imaging and intraoperative assessment. We routinely dissect levels III, IV, and the anterior portion of level VB in all lateral neck dissections but only include levels I, II, and the remainder of level VB in the presence of involved nodes in the adjacent compartment  (<a class="graphic graphic_figure graphicRef54099" href="/z/d/graphic/54099.html" rel="external">figure 2</a>).</p><p>Using a selective approach, a level II neck dissection is required in approximately 21 percent of patients undergoing a therapeutic neck dissection [<a href="#rid14">14</a>]. Most positive level II nodes are located in level IIA, and without clinical or radiographic involvement, level IIB dissection is unnecessary in most patients [<a href="#rid82">82,84</a>]. </p><p>Patients with level II disease typically have positive level III lymph nodes. Therefore, a level II node dissection may be omitted if there is no clinical or histologic evidence of positive level III nodes and no evidence of macroscopic extranodal extension [<a href="#rid85">85</a>]. Based upon a retrospective review of 52 patients with papillary thyroid cancer with no clinical suspicion of positive level II nodes, occult disease was identified in 19 percent (10 patients) [<a href="#rid86">86</a>]. Occult disease was identified only in those patients with imaging suspicious for level III or IV nodal involvement or histologic evidence of positive lymph nodes in level III.</p><p>Level VB nodes are positive in 12 to 40 percent of patients, but involvement of level VA is rare  (<a class="graphic graphic_figure graphicRef54099" href="/z/d/graphic/54099.html" rel="external">figure 2</a>) [<a href="#rid83">83,86</a>]. If there is no evidence of posterior nodal involvement in level V, we confine our dissection anterior to the spinal accessory nerve in order to avoid injury to the nerve. The border between levels III, IV, and V is somewhat arbitrary, likely contributing to the variable rate of dissection and node positivity. </p><p class="headingAnchor" id="H27139949"><span class="h2">Technique for a selective lateral neck dissection</span><span class="headingEndMark"> — </span>The approach to a lateral compartment neck dissection includes  (<a class="graphic graphic_figure graphicRef58086" href="/z/d/graphic/58086.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef54099" href="/z/d/graphic/54099.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef86365" href="/z/d/graphic/86365.html" rel="external">figure 7</a>):</p><p class="headingAnchor" id="H113141971"><span class="h3">Incision</span><span class="headingEndMark"> — </span>The incision for a lateral neck dissection depends upon the operative setting and surgeon preference. It can be a low collar incision or a lateral extension of a higher thyroidectomy incision. If additional exposure is needed to reach level II, the lateral extent of the incision can be brought up along the posterior aspect of the sternocleidomastoid muscle, or a second incision can be placed in a high neck crease to facilitate exposure to this region  (<a class="graphic graphic_figure graphicRef88332" href="/z/d/graphic/88332.html" rel="external">figure 8</a>). An ultrasound performed after the patient has been positioned on the operating table can be helpful to map the extent of the nodal disease and guide optimal incision placement.</p><p class="headingAnchor" id="H113141996"><span class="h3">Dissection of level III and level IV</span><span class="headingEndMark"> — </span>We routinely resect levels III, IV, and the anterior portion of level VB in all lateral neck dissections  (<a class="graphic graphic_figure graphicRef54099" href="/z/d/graphic/54099.html" rel="external">figure 2</a>). </p><p class="bulletIndent1"><span class="glyph">●</span>Begin the dissection inferiorly at the level of the clavicle. Continue the dissection along the internal jugular vein to the anterior scalene muscle. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identify the fibroareolar plane posteriorly. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use sharp dissection techniques, and avoid using electrocautery in the vicinity of major neurovascular structures (eg, jugular vein, vagus nerve).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preserve the thoracic duct as it empties into the internal jugular vein, near the junction with the subclavian vein. A simulated Valsalva maneuver, performed by suspending mechanical ventilation and applying manual compression to the ventilation bag, can facilitate identification of the duct and recognition of an injury. If the thoracic duct is divided, it should be ligated securely but gently to avoid leakage. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identify the vagus nerve within the carotid sheath, posterior and medial to the internal jugular vein. The vagus nerve is spared while dissecting along the vein.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Continue the dissection superiorly and laterally, identifying and preserving the phrenic nerve, located just posterior to the plane of dissection and anterior to the scalene muscle  (<a class="graphic graphic_figure graphicRef52752" href="/z/d/graphic/52752.html" rel="external">figure 9</a> and <a class="graphic graphic_figure graphicRef52959" href="/z/d/graphic/52959.html" rel="external">figure 10</a>). The phrenic nerve is left intact adherent to the scalene muscles while the tissue superior to the nerve is resected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preserve the cervical plexus nerves when possible while dissecting the nodal tissue from level III  (<a class="graphic graphic_figure graphicRef54142" href="/z/d/graphic/54142.html" rel="external">figure 11</a>). The cervical plexus nerves cross the field of dissection. </p><p></p><p class="headingAnchor" id="H113142004"><span class="h3">Dissection of level II and level V</span><span class="headingEndMark"> — </span>We only include dissection levels I, II, and the posterior level VB in the presence of involved nodes in the adjacent compartment (III, IV, and anterior VB).</p><p class="bulletIndent1"><span class="glyph">●</span>Identify the hypoglossal nerve at the superior extent of the lateral dissection, as it crosses superior to the bifurcation of the carotid artery, near the facial vein  (<a class="graphic graphic_figure graphicRef86991" href="/z/d/graphic/86991.html" rel="external">figure 12</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identify the spinal accessory nerve at the lateral extent of the superior dissection  (<a class="graphic graphic_figure graphicRef86991" href="/z/d/graphic/86991.html" rel="external">figure 12</a>). The spinal accessory nerve is the landmark that divides level II into levels IIA and IIB, where it can be identified superior to the greater auricular nerve, which originates posterior to the sternocleidomastoid muscle. Avoid retraction or dissection along the nerve, which is particularly vulnerable to injury during levels IIB and VA dissections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Continue the dissection posteriorly into level VA and superiorly to level IIA. If no further disease is identified, the dissection is concluded here. However, if macroscopic nodal disease is identified at level IIA, proceed with the removal of level IIB nodes. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Insertion of a drain should be done selectively if at all, as it will not prevent bleeding or seroma formation [<a href="#rid87">87-89</a>]. If there is any suspicion of injury to the thoracic duct, a drain should be placed.</p><p></p><p class="headingAnchor" id="H2816053332"><span class="h1">INTRAOPERATIVE ISSUES</span></p><p class="headingAnchor" id="H1858541730"><span class="h2">Intraoperative monitoring</span><span class="headingEndMark"> — </span>At the surgeon's discretion, intraoperative monitoring of the recurrent laryngeal nerve can be used. The technique for intraoperative nerve monitoring is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2157.html" rel="external">"Thyroidectomy", section on 'Intraoperative nerve monitoring'</a>.)</p><p>Intraoperative ultrasound can aid in tumor identification, particularly during a reoperation when the recurrence may not be easily identifiable [<a href="#rid71">71-73</a>]. Using preoperative and intraoperative ultrasound and localization techniques can guide incision placement, direct the dissection, and minimize the risks in the reoperative setting [<a href="#rid70">70-76</a>]. (See <a class="local">'Preoperative localization of recurrent disease'</a> above and <a class="local">'Outcomes'</a> below.)</p><p class="headingAnchor" id="H16738442"><span class="h2">Intraoperative challenges</span><span class="headingEndMark"> — </span>The greatest technical challenges to avoiding injury to vital structures are encountered in the reoperative setting secondary to distortion or obliteration of the anatomic landmarks [<a href="#rid90">90</a>]. Besides that, central and lateral compartment neck dissections each have a unique set of intraoperative challenges.</p><p>The intraoperative challenges for a <strong>central</strong> neck dissection are similar to those for a thyroidectomy and include identification and preservation of nerves (eg, recurrent laryngeal nerve, superior laryngeal nerve), vascular pedicles (eg, superior thyroid artery and vein), parathyroid glands, the trachea, and the esophagus  (<a class="graphic graphic_figure graphicRef58086" href="/z/d/graphic/58086.html" rel="external">figure 1</a>) [<a href="#rid45">45,91,92</a>]. (See  <a class="medical medical_review" href="/z/d/html/2157.html" rel="external">"Thyroidectomy", section on 'Complications'</a>.)</p><p>During a <strong>lateral</strong> neck dissection, the vagus, phrenic, spinal accessory, hypoglossal, greater auricular, sympathetic chain, and cervical sensory nerves are at risk of injury. The spinal accessory nerve is at greatest risk, particularly when levels IIB and VA nodes are dissected  (<a class="graphic graphic_figure graphicRef86991" href="/z/d/graphic/86991.html" rel="external">figure 12</a> and <a class="graphic graphic_figure graphicRef54099" href="/z/d/graphic/54099.html" rel="external">figure 2</a>) [<a href="#rid93">93,94</a>]. </p><p>Additionally, densely adherent nodal disease to the internal jugular vein can require ligation and resection of the vein. However, this procedure can only be safely performed unilaterally in one operative setting to avoid obstruction of cerebral venous outflow [<a href="#rid95">95-97</a>]. (See <a class="local">'Technique for a selective lateral neck dissection'</a> above.)</p><p class="headingAnchor" id="H16738449"><span class="h1">POSTOPERATIVE MANAGEMENT</span><span class="headingEndMark"> — </span>Postoperative care after neck dissections is similar to that after a thyroidectomy and includes management of pain, nausea, and observation for complications such as hypocalcemia, chyle leak, and hematoma formation. Patients are typically admitted for overnight observation but can be discharged home after less extensive neck dissections. (See  <a class="medical medical_review" href="/z/d/html/2157.html" rel="external">"Thyroidectomy", section on 'Postoperative care'</a>.)</p><p>All patients are educated regarding the symptoms of hypocalcemia (eg, perioral numbness, paresthesias of the hands or feet, muscle cramps). After discharge, patients are often instructed to take 1 to 2 grams of oral calcium supplementation (elemental calcium given as <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a> or <a class="drug drug_general" data-topicid="8829" href="/z/d/drug information/8829.html" rel="external">calcium citrate</a>). A typical dose is 2 grams twice daily, but the dose is adjusted to control symptoms and maintain a low-normal serum calcium concentration. (See  <a class="medical medical_review" href="/z/d/html/833.html" rel="external">"Clinical manifestations of hypocalcemia", section on 'Acute manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/826.html" rel="external">"Treatment of hypocalcemia"</a>.)</p><p>For patients undergoing a central neck dissection, serum calcium and parathyroid hormone (PTH) levels can be obtained in the recovery room for outpatients or on the morning of postoperative day 1 prior to discharge for those who are admitted. Calcium supplementation can be based upon the postoperative PTH level using the following algorithm [<a href="#rid98">98</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>PTH &gt;10 pg/mL – Supplement with 1 to 4 g of calcium orally daily. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PTH between 5 to 10 pg/mL – Add 0.25 mcg of <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> twice daily to calcium supplementation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PTH &lt;5 pg/mL – Add 0.5 mcg of <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> twice daily to calcium supplementation. </p><p></p><p>If PTH testing is not available, then symptoms or an algorithm based upon serum calcium levels can be used to determine the need for calcium supplementation  (<a class="graphic graphic_table graphicRef59019" href="/z/d/graphic/59019.html" rel="external">table 2</a>). </p><p>Alternatively, some surgeons prescribe calcium supplementation to all patients in the postoperative period, given the minimal risks and cost of routine calcium supplementation [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/2157.html" rel="external">"Thyroidectomy", section on 'Calcium supplementation'</a> and  <a class="medical medical_review" href="/z/d/html/826.html" rel="external">"Treatment of hypocalcemia"</a> and  <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment", section on 'Hypoparathyroidism'</a> and  <a class="medical medical_review" href="/z/d/html/7880.html" rel="external">"Surgical management of hyperthyroidism", section on 'Hypocalcemia'</a>.)</p><p>If used, a drain is typically removed on postoperative day 1. If a drain was placed to observe for a chyle leak, the patient is given a fatty food challenge and the drain contents examined for milky, opalescent appearance of lymphatic fluid. If a small chyle leak is identified, it may cease with conservative management, such as medium-chain triglyceride diet or <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>. If the output cannot be controlled by diet modification, reoperation with ligation of the thoracic duct, fibrin sealant placement, or flap closure may be required [<a href="#rid99">99</a>]. (See  <a class="medical medical_review" href="/z/d/html/6696.html" rel="external">"Etiology, clinical presentation, and diagnosis of chylothorax", section on 'Pathogenesis and etiology'</a> and  <a class="medical medical_review" href="/z/d/html/16356.html" rel="external">"Management of chylothorax"</a>.)</p><p>Thyroid hormone replacement following a thyroidectomy for differentiated thyroid cancer is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment", section on 'Postoperative thyroid hormone therapy'</a>.)</p><p class="headingAnchor" id="H7046574"><span class="h1">OUTCOMES</span></p><p class="headingAnchor" id="H7048866"><span class="h2">Mortality rates</span><span class="headingEndMark"> — </span>The 30 day mortality rate after thyroidectomy and neck dissection for differentiated thyroid cancer is less than 1 percent [<a href="#rid100">100</a>].</p><p class="headingAnchor" id="H7048874"><span class="h2">Morbidity rates</span><span class="headingEndMark"> — </span>The most common complications following a neck dissection for differentiated thyroid cancer are similar to those following a thyroidectomy and include nerve injury, hypocalcemia, hematoma/seroma formation, and injury to the trachea and esophagus. The extent of the surgical procedure, the experience of the surgeon, and prior neck surgery all contribute to the risk of surgical complications [<a href="#rid101">101,102</a>]. (See  <a class="medical medical_review" href="/z/d/html/2157.html" rel="external">"Thyroidectomy", section on 'Complications'</a>.)</p><p class="headingAnchor" id="H243766697"><span class="h3">Morbidities of central neck dissection</span><span class="headingEndMark"> — </span>In a review of 17 retrospective studies including 1929 patients undergoing a central neck lymph node dissection, the complications and their respective prevalences were [<a href="#rid43">43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Transient hypocalcemia – 3.6 to 60 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Permanent hypocalcemia – 0 to 14.4 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Transient recurrent laryngeal nerve injury – 0 to 25 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Permanent recurrent laryngeal nerve injury – 0 to 11.5 percent</p><p></p><p>While some authors suggest that there is no increased risk of complications when a central neck dissection is performed in conjunction with a total thyroidectomy [<a href="#rid44">44</a>], others have found higher complication rates with an added neck dissection, especially when performed by less experienced surgeons [<a href="#rid43">43,44,53-55,91,103-105</a>]. </p><p>As an example, a review of 1087 patients found higher rates of transient hypoparathyroidism after unilateral or bilateral central neck dissection compared with after total thyroidectomy alone (unilateral: 36.1 versus 27.7 percent; bilateral: 51.9 versus 27.7 percent) [<a href="#rid53">53</a>]. In a randomized trial, permanent hypoparathyroidism was also more common after central neck dissection than after a total thyroidectomy alone (19.4 versus 8.0 percent) [<a href="#rid31">31</a>].</p><p>A bilateral central neck dissection is associated with a higher rate of complications than a unilateral central neck dissection. As an example, in a retrospective review of 103 patients with papillary thyroid cancers &lt;2 cm, patients undergoing a bilateral dissection were significantly more likely to develop transient hypocalcemia compared with patients undergoing a unilateral dissection (48.0 versus 20.5 percent) [<a href="#rid50">50</a>]. </p><p>Reoperation in the central neck can be technically challenging. However, the complication rates are not different from those of initial operations when reoperations are performed by experienced surgeons [<a href="#rid43">43,48,63,90,106</a>]. Based upon a retrospective review of 295 patients undergoing central neck dissections, patients undergoing a reoperation (n = 106) had similar rates of permanent hypocalcemia (0.5 versus 0.9 percent), hematoma formation (1.1 versus 0.9 percent), and permanent hoarseness (2.9 versus 1.9 percent) compared with patients undergoing an initial neck dissection [<a href="#rid106">106</a>]. Only transient hypocalcemia was more common after a reoperation (41.8 versus 23.6 percent). </p><p class="headingAnchor" id="H2851667576"><span class="h3">Morbidities of lateral neck dissection</span><span class="headingEndMark"> — </span>A lateral compartment lymph node dissection, when performed by an experienced surgeon, is associated with a low risk of injury to the spinal accessory, hypoglossal, and vagus nerves; the sympathetic chain (Horner syndrome); and the thoracic duct [<a href="#rid104">104</a>]. Reoperation for nodal disease in the lateral neck is not associated with any higher risk of complications if the lateral neck has not been dissected during the original operation [<a href="#rid106">106</a>]. </p><p>In addition to the more serious complications such as nerve injury, postoperative seromas are common after a lymph node dissection and typically appear four to five days after the operation and then resolve spontaneously. Seromas are not prevented by drain placement at the time of operation [<a href="#rid89">89,107</a>]. Since a small seroma is difficult to discern from normal postoperative swelling, the incidence of this complication is difficult to define. However, occasionally seromas become large and symptomatic and require percutaneous aspiration for symptom relief. Seromas requiring percutaneous drainage are uncommon, occurring in &lt;7 percent of patients [<a href="#rid89">89,107</a>]. </p><p class="headingAnchor" id="H7046801"><span class="h2">Nodal recurrence</span><span class="headingEndMark"> — </span>The nodal recurrence rate following a therapeutic neck dissection ranges from 28 to 38 percent [<a href="#rid21">21,62,106</a>]. In a retrospective review of 45 patients undergoing a therapeutic neck dissection for recurrent thyroid cancer, 17 patients (38 percent) developed a second recurrence [<a href="#rid62">62</a>]. If the nodal disease was located outside a previously dissected level at the time of the therapeutic neck dissection, the overall nodal recurrence rate was 28 percent [<a href="#rid62">62</a>]. (See <a class="local">'Recurrent nodal disease'</a> above.)</p><p class="headingAnchor" id="H1493680411"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/129060.html" rel="external">"Society guideline links: Thyroid surgery"</a>.)</p><p class="headingAnchor" id="H27140051"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with differentiated thyroid cancer but without evidence of nodal involvement  (<a class="graphic graphic_algorithm graphicRef113321" href="/z/d/graphic/113321.html" rel="external">algorithm 1</a>): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A prophylactic neck dissection is <strong>not</strong> performed for patients known preoperatively to have <strong>follicular</strong> thyroid cancer, because the risk of nodal disease is low.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We <strong>do not routinely</strong> perform central neck dissection (level VI) for <strong>papillary</strong> thyroid cancer, since the benefits of prophylactic dissection appear small and the risk of transient complications is high. However, for those with a large primary cancer (T3/4) or high-risk features for recurrence (eg, <em>BRAF</em> mutations, extrathyroidal tumor extension), a prophylactic central neck dissection is an option that can potentially negate a reoperation. (See <a class="local">'Choosing a neck dissection technique'</a> above and  <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment", section on 'Approach to lymph node dissection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with differentiated thyroid cancer and evidence of nodal involvement (ie, clinical or radiographic evidence confirmed by fine-needle aspiration), we recommend a therapeutic neck dissection  (<a class="graphic graphic_algorithm graphicRef113321" href="/z/d/graphic/113321.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Choosing a neck dissection technique'</a> above and  <a class="medical medical_review" href="/z/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment", section on 'Approach to lymph node dissection'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a nodal recurrence following a thyroidectomy without a previous lymphadenectomy, we recommend a therapeutic compartment-oriented neck dissection  (<a class="graphic graphic_algorithm graphicRef113321" href="/z/d/graphic/113321.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Known nodal disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a recurrence following a therapeutic neck dissection, we suggest a focused excision of the lesion that is ≥8 mm in the central neck and ≥10 mm in the lateral neck (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). If the recurrence is located in an anatomic level not previously dissected, we suggest a therapeutic lymph node dissection of that level (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Suspected nodal recurrences that are smaller may be observed with serial imaging  (<a class="graphic graphic_algorithm graphicRef113321" href="/z/d/graphic/113321.html" rel="external">algorithm 1</a>). (See <a class="local">'Recurrent nodal disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The central compartment neck dissection extends superiorly to the hyoid bone and inferiorly to the innominate (brachiocephalic) artery  (<a class="graphic graphic_figure graphicRef58086" href="/z/d/graphic/58086.html" rel="external">figure 1</a>). The lateral border of dissection is the ipsilateral carotid artery, the anterior border is the superficial layer of the deep cervical fascia, and the posterior border is the deep layer of the deep cervical fascia, which may be deep to the carotid artery. It can be performed in conjunction with a thyroidectomy or as a separate procedure for recurrent differentiated thyroid cancer. (See <a class="local">'Central compartment neck dissection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The extensiveness of a lateral compartment lymph node dissection generally depends upon the location of the nodal disease (eg, most commonly level III and IV) and surgeon preference and is controversial. For therapeutic purposes, we routinely dissect levels III, IV, and the anterior portion of level VB. We dissect levels II and posterior VB if diseases are present in adjacent levels. "Berry picking" of clinically involved nodes should not be performed for therapeutic purposes. (See <a class="local">'Therapeutic lateral compartment neck dissection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nodal recurrence rate following a therapeutic neck dissection ranges from 28 to 38 percent. Reoperative neck dissection is most technically challenging and risky for complications secondary to distortion or obliteration of the anatomic landmarks by scar tissues. Preoperative marking with blue dye or charcoal suspension and intraoperative ultrasound can facilitate identification of pathologic nodes. When necessary, a fresh incision can be made directly over a localized lymph node to avoid extensive dissection. (See <a class="local">'Recurrent nodal disease'</a> above and <a class="local">'Preoperative localization of recurrent disease'</a> above and <a class="local">'Intraoperative challenges'</a> above and <a class="local">'Nodal recurrence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When performed by experienced surgeons, neck dissection is associated with low morbidity and mortality rates. Major morbidities of neck dissection are similar to those of thyroidectomy and include nerve injury, hypocalcemia, hematoma/seroma formation, and injury to the trachea and esophagus. (See <a class="local">'Outcomes'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295:2164.</a></li><li><a class="nounderline abstract_t">Robbins KT, Clayman G, Levine PA, et al. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. Arch Otolaryngol Head Neck Surg 2002; 128:751.</a></li><li><a class="nounderline abstract_t">American Thyroid Association Surgery Working Group, American Association of Endocrine Surgeons,, American Academy of Otolaryngology-Head and Neck Surgery, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid 2009; 19:1153.</a></li><li><a class="nounderline abstract_t">Musacchio MJ, Kim AW, Vijungco JD, Prinz RA. Greater local recurrence occurs with "berry picking" than neck dissection in thyroid cancer. Am Surg 2003; 69:191.</a></li><li><a class="nounderline abstract_t">Grubbs EG, Evans DB. Role of lymph node dissection in primary surgery for thyroid cancer. J Natl Compr Canc Netw 2007; 5:623.</a></li><li><a class="nounderline abstract_t">Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003; 13:381.</a></li><li><a class="nounderline abstract_t">Kim E, Park JS, Son KR, et al. Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography. Thyroid 2008; 18:411.</a></li><li><a class="nounderline abstract_t">Stulak JM, Grant CS, Farley DR, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg 2006; 141:489.</a></li><li><a class="nounderline abstract_t">Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26:1.</a></li><li><a class="nounderline abstract_t">Arturi F, Russo D, Giuffrida D, et al. Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. J Clin Endocrinol Metab 1997; 82:1638.</a></li><li><a class="nounderline abstract_t">Noguchi S, Noguchi A, Murakami N. Papillary carcinoma of the thyroid. I. Developing pattern of metastasis. Cancer 1970; 26:1053.</a></li><li><a class="nounderline abstract_t">Qubain SW, Nakano S, Baba M, et al. Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. Surgery 2002; 131:249.</a></li><li><a class="nounderline abstract_t">Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery 2008; 144:1070.</a></li><li><a class="nounderline abstract_t">Caron NR, Tan YY, Ogilvie JB, et al. Selective modified radical neck dissection for papillary thyroid cancer-is level I, II and V dissection always necessary? World J Surg 2006; 30:833.</a></li><li><a class="nounderline abstract_t">Chung YS, Kim JY, Bae JS, et al. Lateral lymph node metastasis in papillary thyroid carcinoma: results of therapeutic lymph node dissection. Thyroid 2009; 19:241.</a></li><li><a class="nounderline abstract_t">Park JH, Lee YS, Kim BW, et al. Skip lateral neck node metastases in papillary thyroid carcinoma. World J Surg 2012; 36:743.</a></li><li><a class="nounderline abstract_t">Howell GM, Nikiforova MN, Carty SE, et al. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol 2013; 20:47.</a></li><li><a class="nounderline abstract_t">Zhang L, Wei WJ, Ji QH, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab 2012; 97:1250.</a></li><li><a class="nounderline abstract_t">Koo BS, Choi EC, Yoon YH, et al. Predictive factors for ipsilateral or contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma. Ann Surg 2009; 249:840.</a></li><li><a class="nounderline abstract_t">Roh JL, Kim JM, Park CI. Central lymph node metastasis of unilateral papillary thyroid carcinoma: patterns and factors predictive of nodal metastasis, morbidity, and recurrence. Ann Surg Oncol 2011; 18:2245.</a></li><li><a class="nounderline abstract_t">Randolph GW, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 2012; 22:1144.</a></li><li><a class="nounderline abstract_t">Moreno MA, Edeiken-Monroe BS, Siegel ER, et al. In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival. Thyroid 2012; 22:347.</a></li><li><a class="nounderline abstract_t">Smith VA, Sessions RB, Lentsch EJ. Cervical lymph node metastasis and papillary thyroid carcinoma: does the compartment involved affect survival? Experience from the SEER database. J Surg Oncol 2012; 106:357.</a></li><li><a class="nounderline abstract_t">Wada N, Duh QY, Sugino K, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 2003; 237:399.</a></li><li><a class="nounderline abstract_t">Ito Y, Tomoda C, Uruno T, et al. Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid. World J Surg 2004; 28:498.</a></li><li><a class="nounderline abstract_t">Wada N, Masudo K, Nakayama H, et al. Clinical outcomes in older or younger patients with papillary thyroid carcinoma: impact of lymphadenopathy and patient age. Eur J Surg Oncol 2008; 34:202.</a></li><li><a class="nounderline abstract_t">Gemsenjäger E, Perren A, Seifert B, et al. Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg 2003; 197:182.</a></li><li><a class="nounderline abstract_t">Schneider DF, Mazeh H, Chen H, Sippel RS. Lymph node ratio predicts recurrence in papillary thyroid cancer. Oncologist 2013; 18:157.</a></li><li><a class="nounderline abstract_t">Wada N, Suganuma N, Nakayama H, et al. Microscopic regional lymph node status in papillary thyroid carcinoma with and without lymphadenopathy and its relation to outcomes. Langenbecks Arch Surg 2007; 392:417.</a></li><li><a class="nounderline abstract_t">Bardet S, Malville E, Rame JP, et al. Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur J Endocrinol 2008; 158:551.</a></li><li><a class="nounderline abstract_t">Viola D, Materazzi G, Valerio L, et al. Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. J Clin Endocrinol Metab 2015; 100:1316.</a></li><li><a class="nounderline abstract_t">Calò PG, Conzo G, Raffaelli M, et al. Total thyroidectomy alone versus ipsilateral versus bilateral prophylactic central neck dissection in clinically node-negative differentiated thyroid carcinoma. A retrospective multicenter study. Eur J Surg Oncol 2017; 43:126.</a></li><li><a class="nounderline abstract_t">Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer 2006; 106:524.</a></li><li><a class="nounderline abstract_t">Scheumann GF, Gimm O, Wegener G, et al. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 1994; 18:559.</a></li><li><a class="nounderline abstract_t">Shah MD, Hall FT, Eski SJ, et al. Clinical course of thyroid carcinoma after neck dissection. Laryngoscope 2003; 113:2102.</a></li><li><a class="nounderline abstract_t">Eustatia-Rutten CF, Corssmit EP, Biermasz NR, et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91:313.</a></li><li><a class="nounderline abstract_t">Podnos YD, Smith D, Wagman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg 2005; 71:731.</a></li><li><a class="nounderline abstract_t">Noguchi S, Murakami N, Yamashita H, et al. Papillary thyroid carcinoma: modified radical neck dissection improves prognosis. Arch Surg 1998; 133:276.</a></li><li><a class="nounderline abstract_t">Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16:109.</a></li><li><a class="nounderline abstract_t">Yeh MW, Bauer AJ, Bernet VA, et al. American Thyroid Association statement on preoperative imaging for thyroid cancer surgery. Thyroid 2015; 25:3.</a></li><li><a class="nounderline abstract_t">Choi JS, Kim J, Kwak JY, et al. Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT. AJR Am J Roentgenol 2009; 193:871.</a></li><li><a class="nounderline abstract_t">Kaplan SL, Mandel SJ, Muller R, et al. The role of MR imaging in detecting nodal disease in thyroidectomy patients with rising thyroglobulin levels. AJNR Am J Neuroradiol 2009; 30:608.</a></li><li><a class="nounderline abstract_t">Sippel RS, Chen H. Controversies in the surgical management of newly diagnosed and recurrent/residual thyroid cancer. Thyroid 2009; 19:1373.</a></li><li><a class="nounderline abstract_t">Chisholm EJ, Kulinskaya E, Tolley NS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope 2009; 119:1135.</a></li><li><a class="nounderline abstract_t">Ondik MP, Dezfoli S, Lipinski L, et al. Secondary central compartment surgery for thyroid cancer. Laryngoscope 2009; 119:1947.</a></li><li><a class="nounderline abstract_t">Bonnet S, Hartl D, Leboulleux S, et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab 2009; 94:1162.</a></li><li><a class="nounderline abstract_t">Mazzaferri EL, Doherty GM, Steward DL. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid 2009; 19:683.</a></li><li><a class="nounderline abstract_t">Alvarado R, Sywak MS, Delbridge L, Sidhu SB. Central lymph node dissection as a secondary procedure for papillary thyroid cancer: Is there added morbidity? Surgery 2009; 145:514.</a></li><li><a class="nounderline abstract_t">Clayman GL, Shellenberger TD, Ginsberg LE, et al. Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. Head Neck 2009; 31:1152.</a></li><li><a class="nounderline abstract_t">Lee YS, Kim SW, Kim SW, et al. Extent of routine central lymph node dissection with small papillary thyroid carcinoma. World J Surg 2007; 31:1954.</a></li><li><a class="nounderline abstract_t">Cavicchi O, Piccin O, Caliceti U, et al. Transient hypoparathyroidism following thyroidectomy: a prospective study and multivariate analysis of 604 consecutive patients. Otolaryngol Head Neck Surg 2007; 137:654.</a></li><li><a class="nounderline abstract_t">Patel KN, Yip L, Lubitz CC, et al. The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults. Ann Surg 2020; 271:e21.</a></li><li><a class="nounderline abstract_t">Giordano D, Valcavi R, Thompson GB, et al. Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature. Thyroid 2012; 22:911.</a></li><li><a class="nounderline abstract_t">So YK, Seo MY, Son YI. Prophylactic central lymph node dissection for clinically node-negative papillary thyroid microcarcinoma: influence on serum thyroglobulin level, recurrence rate, and postoperative complications. Surgery 2012; 151:192.</a></li><li><a class="nounderline abstract_t">Wang TS, Cheung K, Farrokhyar F, et al. A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer. Ann Surg Oncol 2013; 20:3477.</a></li><li><a class="nounderline abstract_t">Tisell LE, Nilsson B, Mölne J, et al. Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg 1996; 20:854.</a></li><li><a class="nounderline abstract_t">Barczyński M, Konturek A, Stopa M, Nowak W. Prophylactic central neck dissection for papillary thyroid cancer. Br J Surg 2013; 100:410.</a></li><li><a class="nounderline abstract_t">Zhao W, You L, Hou X, et al. The Effect of Prophylactic Central Neck Dissection on Locoregional Recurrence in Papillary Thyroid Cancer After Total Thyroidectomy: A Systematic Review and Meta-Analysis : pCND for the Locoregional Recurrence of Papillary Thyroid Cancer. Ann Surg Oncol 2017; 24:2189.</a></li><li><a class="nounderline abstract_t">Sippel RS, Robbins SE, Poehls JL, et al. A Randomized Controlled Clinical Trial: No Clear Benefit to Prophylactic Central Neck Dissection in Patients With Clinically Node Negative Papillary Thyroid Cancer. Ann Surg 2020; 272:496.</a></li><li><a class="nounderline abstract_t">Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 2002; 26:22.</a></li><li class="breakAll">https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf (Accessed on February 19, 2020).</li><li><a class="nounderline abstract_t">Uruno T, Miyauchi A, Shimizu K, et al. Prognosis after reoperation for local recurrence of papillary thyroid carcinoma. Surg Today 2004; 34:891.</a></li><li><a class="nounderline abstract_t">Schuff KG, Weber SM, Givi B, et al. Efficacy of nodal dissection for treatment of persistent/recurrent papillary thyroid cancer. Laryngoscope 2008; 118:768.</a></li><li><a class="nounderline abstract_t">Robenshtok E, Fish S, Bach A, et al. Suspicious cervical lymph nodes detected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients. J Clin Endocrinol Metab 2012; 97:2706.</a></li><li><a class="nounderline abstract_t">Kim SY, Kim SM, Chang H, et al. Long-term outcomes of ethanol injection therapy for locally recurrent papillary thyroid cancer. Eur Arch Otorhinolaryngol 2017; 274:3497.</a></li><li><a class="nounderline abstract_t">Suh CH, Baek JH, Choi YJ, Lee JH. Efficacy and Safety of Radiofrequency and Ethanol Ablation for Treating Locally Recurrent Thyroid Cancer: A Systematic Review and Meta-Analysis. Thyroid 2016; 26:420.</a></li><li><a class="nounderline abstract_t">Hay ID, Lee RA, Davidge-Pitts C, et al. Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected "recurrent" neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy. Surgery 2013; 154:1448.</a></li><li><a class="nounderline abstract_t">Buerba R, Roman SA, Sosa JA. Thyroidectomy and parathyroidectomy in patients with high body mass index are safe overall: analysis of 26,864 patients. Surgery 2011; 150:950.</a></li><li><a class="nounderline abstract_t">Roy M, Rajamanickam V, Chen H, Sippel R. Is DVT prophylaxis necessary for thyroidectomy and parathyroidectomy? Surgery 2010; 148:1163.</a></li><li><a class="nounderline abstract_t">McCoy KL, Yim JH, Tublin ME, et al. Same-day ultrasound guidance in reoperation for locally recurrent papillary thyroid cancer. Surgery 2007; 142:965.</a></li><li><a class="nounderline abstract_t">Desai D, Jeffrey RB, McDougall IR, Weigel RJ. Intraoperative ultrasonography for localization of recurrent thyroid cancer. Surgery 2001; 129:498.</a></li><li><a class="nounderline abstract_t">Karwowski JK, Jeffrey RB, McDougall IR, Weigel RJ. Intraoperative ultrasonography improves identification of recurrent thyroid cancer. Surgery 2002; 132:924.</a></li><li><a class="nounderline abstract_t">Zimmerman P, DaSilva M, Izquierdo R, et al. Intraoperative needle localization during neck reexploration. Am J Surg 2004; 188:92.</a></li><li><a class="nounderline abstract_t">Triponez F, Poder L, Zarnegar R, et al. Hook needle-guided excision of recurrent differentiated thyroid cancer in previously operated neck compartments: a safe technique for small, nonpalpable recurrent disease. J Clin Endocrinol Metab 2006; 91:4943.</a></li><li><a class="nounderline abstract_t">Sippel RS, Elaraj DM, Poder L, et al. Localization of recurrent thyroid cancer using intraoperative ultrasound-guided dye injection. World J Surg 2009; 33:434.</a></li><li><a class="nounderline abstract_t">Hartl DM, Chami L, Al Ghuzlan A, et al. Charcoal suspension tattoo localization for differentiated thyroid cancer recurrence. Ann Surg Oncol 2009; 16:2602.</a></li><li><a class="nounderline abstract_t">Ofo E, Thavaraj S, Cope D, et al. Quantification of lymph nodes in the central compartment of the neck: a cadaveric study. Eur Arch Otorhinolaryngol 2016; 273:2773.</a></li><li><a class="nounderline abstract_t">Nobori M, Saiki S, Tanaka N, et al. Blood supply of the parathyroid gland from the superior thyroid artery. Surgery 1994; 115:417.</a></li><li><a class="nounderline abstract_t">Sakorafas GH, Sampanis D, Safioleas M. Cervical lymph node dissection in papillary thyroid cancer: current trends, persisting controversies, and unclarified uncertainties. Surg Oncol 2010; 19:e57.</a></li><li><a class="nounderline abstract_t">Khafif A, Medina JE, Robbins KT, et al. Level V in therapeutic neck dissections for papillary thyroid carcinoma. Head Neck 2013; 35:605.</a></li><li><a class="nounderline abstract_t">Stack BC Jr, Ferris RL, Goldenberg D, et al. American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer. Thyroid 2012; 22:501.</a></li><li><a class="nounderline abstract_t">Farrag T, Lin F, Brownlee N, et al. Is routine dissection of level II-B and V-A necessary in patients with papillary thyroid cancer undergoing lateral neck dissection for FNA-confirmed metastases in other levels. World J Surg 2009; 33:1680.</a></li><li><a class="nounderline abstract_t">Merdad M, Eskander A, Kroeker T, Freeman JL. Metastatic papillary thyroid cancer with lateral neck disease: pattern of spread by level. Head Neck 2013; 35:1439.</a></li><li><a class="nounderline abstract_t">Lee J, Sung TY, Nam KH, et al. Is level IIb lymph node dissection always necessary in N1b papillary thyroid carcinoma patients? World J Surg 2008; 32:716.</a></li><li><a class="nounderline abstract_t">Kang BC, Roh JL, Lee JH, et al. Candidates for limited lateral neck dissection among patients with metastatic papillary thyroid carcinoma. World J Surg 2014; 38:863.</a></li><li><a class="nounderline abstract_t">Koo BS, Seo ST, Lee GH, et al. Prophylactic lymphadenectomy of neck level II in clinically node-positive papillary thyroid carcinoma. Ann Surg Oncol 2010; 17:1637.</a></li><li><a class="nounderline abstract_t">Khanna J, Mohil RS, Chintamani, et al. Is the routine drainage after surgery for thyroid necessary? A prospective randomized clinical study [ISRCTN63623153]. BMC Surg 2005; 5:11.</a></li><li><a class="nounderline abstract_t">Sanabria A, Carvalho AL, Silver CE, et al. Routine drainage after thyroid surgery--a meta-analysis. J Surg Oncol 2007; 96:273.</a></li><li><a class="nounderline abstract_t">Mekel M, Stephen AE, Gaz RD, et al. Surgical drains can be safely avoided in lateral neck dissections for papillary thyroid cancer. Am J Surg 2010; 199:485.</a></li><li><a class="nounderline abstract_t">Kim MK, Mandel SH, Baloch Z, et al. Morbidity following central compartment reoperation for recurrent or persistent thyroid cancer. Arch Otolaryngol Head Neck Surg 2004; 130:1214.</a></li><li><a class="nounderline abstract_t">Henry JF, Gramatica L, Denizot A, et al. Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg 1998; 383:167.</a></li><li><a class="nounderline abstract_t">Roh JL, Park JY, Park CI. Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg 2007; 245:604.</a></li><li><a class="nounderline abstract_t">Lima LP, Amar A, Lehn CN. Spinal accessory nerve neuropathy following neck dissection. Braz J Otorhinolaryngol 2011; 77:259.</a></li><li><a class="nounderline abstract_t">Cappiello J, Piazza C, Nicolai P. The spinal accessory nerve in head and neck surgery. Curr Opin Otolaryngol Head Neck Surg 2007; 15:107.</a></li><li><a class="nounderline abstract_t">Beahrs OH. Surgical anatomy and technique of radical neck dissection. Surg Clin North Am 1977; 57:663.</a></li><li><a class="nounderline abstract_t">Weiss KL, Wax MK, Haydon RC 3rd, et al. Intracranial pressure changes during bilateral radical neck dissections. Head Neck 1993; 15:546.</a></li><li><a class="nounderline abstract_t">Chai PJ, Skaryak LA, Ungerleider RM, et al. Jugular ligation does not increase intracranial pressure but does increase bihemispheric cerebral blood flow and metabolism. Crit Care Med 1995; 23:1864.</a></li><li><a class="nounderline abstract_t">Youngwirth L, Benavidez J, Sippel R, Chen H. Postoperative parathyroid hormone testing decreases symptomatic hypocalcemia and associated emergency room visits after total thyroidectomy. Surgery 2010; 148:841.</a></li><li><a class="nounderline abstract_t">Shaha AR. Complications of neck dissection for thyroid cancer. Ann Surg Oncol 2008; 15:397.</a></li><li><a class="nounderline abstract_t">Gupta PK, Smith RB, Gupta H, et al. Outcomes after thyroidectomy and parathyroidectomy. Head Neck 2012; 34:477.</a></li><li><a class="nounderline abstract_t">Sosa JA, Bowman HM, Tielsch JM, et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998; 228:320.</a></li><li><a class="nounderline abstract_t">Friedman M, Pacella BL Jr. Total versus subtotal thyroidectomy. Arguments, approaches, and recommendations. Otolaryngol Clin North Am 1990; 23:413.</a></li><li><a class="nounderline abstract_t">Toniato A, Boschin IM, Piotto A, et al. Complications in thyroid surgery for carcinoma: one institution's surgical experience. World J Surg 2008; 32:572.</a></li><li><a class="nounderline abstract_t">Cheah WK, Arici C, Ituarte PH, et al. Complications of neck dissection for thyroid cancer. World J Surg 2002; 26:1013.</a></li><li><a class="nounderline abstract_t">Rubello D, Salvatori M, Casara D, et al. 99mTc-sestamibi radio-guided surgery of loco-regional 131Iodine-negative recurrent thyroid cancer. Eur J Surg Oncol 2007; 33:902.</a></li><li><a class="nounderline abstract_t">Shen WT, Ogawa L, Ruan D, et al. Central neck lymph node dissection for papillary thyroid cancer: comparison of complication and recurrence rates in 295 initial dissections and reoperations. Arch Surg 2010; 145:272.</a></li><li><a class="nounderline abstract_t">Lee SW, Choi EC, Lee YM, et al. Is lack of placement of drains after thyroidectomy with central neck dissection safe? A prospective, randomized study. Laryngoscope 2006; 116:1632.</a></li></ol></div><div id="topicVersionRevision">Topic 15033 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16684987" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Increasing incidence of thyroid cancer in the United States, 1973-2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12117328" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19860578" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Consensus statement on the terminology and classification of central neck dissection for thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12678473" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Greater local recurrence occurs with "berry picking" than neck dissection in thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17623613" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Role of lymph node dissection in primary surgery for thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12804106" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18358074" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16702521" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26462967" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9141564" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5476786" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Papillary carcinoma of the thyroid. I. Developing pattern of metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11894028" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19041020" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16555024" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Selective modified radical neck dissection for papillary thyroid cancer-is level I, II and V dissection always necessary?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19265495" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Lateral lymph node metastasis in papillary thyroid carcinoma: results of therapeutic lymph node dissection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22354485" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Skip lateral neck node metastases in papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22941165" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22319042" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19387316" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Predictive factors for ipsilateral or contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21327454" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Central lymph node metastasis of unilateral papillary thyroid carcinoma: patterns and factors predictive of nodal metastasis, morbidity, and recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23083442" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22280230" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22392921" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cervical lymph node metastasis and papillary thyroid carcinoma: does the compartment involved affect survival? Experience from the SEER database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12616125" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15085396" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18023321" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical outcomes in older or younger patients with papillary thyroid carcinoma: impact of lymphadenopathy and patient age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12892795" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Lymph node surgery in papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23345543" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Lymph node ratio predicts recurrence in papillary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17562092" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Microscopic regional lymph node status in papillary thyroid carcinoma with and without lymphadenopathy and its relation to outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18362303" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25590215" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27780677" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Total thyroidectomy alone versus ipsilateral versus bilateral prophylactic central neck dissection in clinically node-negative differentiated thyroid carcinoma. A retrospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16369995" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7725745" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14660910" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical course of thyroid carcinoma after neck dissection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16263822" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Survival and death causes in differentiated thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16468507" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9517740" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Papillary thyroid carcinoma: modified radical neck dissection improves prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16420177" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25188202" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : American Thyroid Association statement on preoperative imaging for thyroid cancer surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19696304" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19039052" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The role of MR imaging in detecting nodal disease in thyroidectomy patients with rising thyroglobulin levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20001719" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Controversies in the surgical management of newly diagnosed and recurrent/residual thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19358241" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19650129" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Secondary central compartment surgery for thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19116234" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19583485" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19375610" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Central lymph node dissection as a secondary procedure for papillary thyroid cancer: Is there added morbidity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19360746" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17687598" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Extent of routine central lymph node dissection with small papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17903586" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Transient hypoparathyroidism following thyroidectomy: a prospective study and multivariate analysis of 604 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32079830" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22827494" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21497873" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prophylactic central lymph node dissection for clinically node-negative papillary thyroid microcarcinoma: influence on serum thyroglobulin level, recurrence rate, and postoperative complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23846784" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8678962" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Improved survival of patients with papillary thyroid cancer after surgical microdissection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23188784" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Prophylactic central neck dissection for papillary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27913945" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The Effect of Prophylactic Central Neck Dissection on Locoregional Recurrence in Papillary Thyroid Cancer After Total Thyroidectomy: A Systematic Review and Meta-Analysis : pCND for the Locoregional Recurrence of Papillary Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33759836" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A Randomized Controlled Clinical Trial: No Clear Benefit to Prophylactic Central Neck Dissection in Patients With Clinically Node Negative Papillary Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11898029" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pattern of nodal metastasis for primary and reoperative thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11898029" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pattern of nodal metastasis for primary and reoperative thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15526121" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prognosis after reoperation for local recurrence of papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18197134" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Efficacy of nodal dissection for treatment of persistent/recurrent papillary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22639292" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Suspicious cervical lymph nodes detected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28664330" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Long-term outcomes of ethanol injection therapy for locally recurrent papillary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26782174" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Efficacy and Safety of Radiofrequency and Ethanol Ablation for Treating Locally Recurrent Thyroid Cancer: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24176579" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected "recurrent" neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21621238" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Thyroidectomy and parathyroidectomy in patients with high body mass index are safe overall: analysis of 26,864 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21134547" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Is DVT prophylaxis necessary for thyroidectomy and parathyroidectomy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18063083" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Same-day ultrasound guidance in reoperation for locally recurrent papillary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11283542" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Intraoperative ultrasonography for localization of recurrent thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12490837" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Intraoperative ultrasonography improves identification of recurrent thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15219493" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Intraoperative needle localization during neck reexploration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16968803" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Hook needle-guided excision of recurrent differentiated thyroid cancer in previously operated neck compartments: a safe technique for small, nonpalpable recurrent disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18958519" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Localization of recurrent thyroid cancer using intraoperative ultrasound-guided dye injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19551443" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Charcoal suspension tattoo localization for differentiated thyroid cancer recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26589898" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Quantification of lymph nodes in the central compartment of the neck: a cadaveric study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8165531" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Blood supply of the parathyroid gland from the superior thyroid artery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19447608" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Cervical lymph node dissection in papillary thyroid cancer: current trends, persisting controversies, and unclarified uncertainties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22287259" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Level V in therapeutic neck dissections for papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22435914" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19506945" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Is routine dissection of level II-B and V-A necessary in patients with papillary thyroid cancer undergoing lateral neck dissection for FNA-confirmed metastases in other levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22965902" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Metastatic papillary thyroid cancer with lateral neck disease: pattern of spread by level.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18087766" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Is level IIb lymph node dissection always necessary in N1b papillary thyroid carcinoma patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24337241" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Candidates for limited lateral neck dissection among patients with metastatic papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20146100" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Prophylactic lymphadenectomy of neck level II in clinically node-positive papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15946379" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Is the routine drainage after surgery for thyroid necessary? A prospective randomized clinical study [ISRCTN63623153].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17469110" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Routine drainage after thyroid surgery--a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20359568" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Surgical drains can be safely avoided in lateral neck dissections for papillary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15492172" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Morbidity following central compartment reoperation for recurrent or persistent thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9641892" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17414610" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21537629" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Spinal accessory nerve neuropathy following neck dissection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17413412" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The spinal accessory nerve in head and neck surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/897962" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Surgical anatomy and technique of radical neck dissection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8253563" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Intracranial pressure changes during bilateral radical neck dissections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7587263" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Jugular ligation does not increase intracranial pressure but does increase bihemispheric cerebral blood flow and metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20723956" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Postoperative parathyroid hormone testing decreases symptomatic hypocalcemia and associated emergency room visits after total thyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18058179" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Complications of neck dissection for thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21638513" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Outcomes after thyroidectomy and parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9742915" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The importance of surgeon experience for clinical and economic outcomes from thyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2195431" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Total versus subtotal thyroidectomy. Arguments, approaches, and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18204947" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Complications in thyroid surgery for carcinoma: one institution's surgical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12045861" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Complications of neck dissection for thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17267163" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : 99mTc-sestamibi radio-guided surgery of loco-regional 131Iodine-negative recurrent thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231628" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Central neck lymph node dissection for papillary thyroid cancer: comparison of complication and recurrence rates in 295 initial dissections and reoperations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16954994" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Is lack of placement of drains after thyroidectomy with central neck dissection safe? A prospective, randomized study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
